Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (Nasdaq: MNKD) has appointed Lauren Sabella as Executive Vice President and Chief Operating Officer effective March 27, 2023. Reporting directly to CEO Michael Castagna, Sabella brings over 12 years of experience from Acorda Therapeutics, where she served as COO. Her previous roles include Chief Commercial Officer and Vice President of Commercial Development, contributing to significant product launches with peak sales exceeding $1 billion. Sabella will oversee critical operations in Danbury, focusing on expanding MannKind's endocrine business and preparing to launch new products in the orphan lung disease market.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 2:00 PM (ET). Interested parties can access the live webcast through the company's website, with a replay available for 14 days after the event.
MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices for effective medicine delivery. The company is committed to addressing medical needs related to diabetes and pulmonary diseases.
MannKind Corporation (Nasdaq: MNKD) reported a total revenue of $100 million for 2022, reflecting a 32% increase from 2021. The fourth quarter revenues reached $36 million, a significant 188% rise year-over-year. Notable contributors include $12 million from Afrezza, with a gross margin of 92%, and $5 million from the newly acquired V-Go product. However, collaborations and services saw a 23% decline year-over-year, primarily due to the conclusion of a partnership with United Therapeutics. The company held $173 million in cash and equivalents at year-end, supporting ongoing R&D investments, including a Phase 3 trial for Afrezza in pediatrics.
MannKind Corporation (Nasdaq: MNKD) announced that its inhaled Technosphere Insulin (TI) demonstrated faster glucose control in a recent pilot study, lowering peak glucose levels 30 minutes faster than traditional rapid-acting insulin via an Automated Insulin Delivery (AID) system. The study involved 26 adults with type 1 diabetes, with TI achieving a lower post-prandial glucose from 45 to 120 minutes post-meal. MannKind plans a larger study to further explore TI's efficiency compared to traditional insulin methods, aiming to improve mealtime glucose control significantly.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
